And just a reminder of the potential of CHM NK Platform.Our NK...

And just a reminder of the potential of CHM NK Platform.

• Our NK platform is derived from peripheral blood from a universal healthy donor without HLA matching. This is important for our development as it means that we do not need to match donors and recipients and can build our platform cells directly from peripheral blood -instead of something like cord blood.
• Our NK platform is irradiated with a unique(NKF) feeder cell line (OCI-AML3+mbIL-21) with unique IP that provides long term protection
• We have been able to complete the development of a FDA approved master cell bank
• We have demonstrated robust ex vivo expansion – up to 30,000 fold with highly active cells
• We have been able to achieve successful manufacturing in large quantities - giving us ~1000 doses per expansion
• We have demonstrated evidence of 28 day persistence of the NK cells
• We have now demonstrated enhanced cytotoxic activity in both preclinical models and now also in the phase 1 clinical trial
• We have demonstrated that the NK cells expanded through this platform have enhanced metabolic activation and expression of activating NK receptors